NEW YORK (
CHANGE IN RATINGS
(ALL - Get Report)
downgraded at FBR from Outperform to Market Perform, FBR Capital said. $40 price target Stock is already pricing in lower catastrophe losses.
Abercrombie & Fitch
(ANF - Get Report)
rated new Underperform at Credit Suisse. $32 price target. Turnaround is not imminent as promotional activity remains high.
downgraded at Jefferies to Hold from Buy, Jefferies said. $56 price target. Several catalysts have past.
upgraded to buy at TheStreet Ratings
downgraded to hold at TheStreet Ratings
(BIDU - Get Report)
downgraded at Jefferies to Hold from Buy, Jefferies said. $125 price target. Search traffic market share shift.
(C - Get Report)
downgraded at Sterne Agee from Buy to Neutral, Sterne Agee said. $33 price target. Stocks has rallied 30% since July, but the company lacks near-term catalysts.
upgraded at Sterne Agee to Buy, Sterne Agee said. $65 price target. Estimates also boosted, as margin fundamentals are improving.
downgraded at FBR from Outperform to Market Perform, FBR Capital said. Valuation call, based on a $26 price target.
upgraded at Sterne Agee from Underperform to Neutral, Sterne Agee said. Estimates also boosted, given the impact of the Macy's deal.
downgraded at KBW from Outperform to Market Perform, Keefe, Bruyette & Woods said. Valuation call, based on a $17 price target.
Healthcare Services Group
rated new Buy at UBS. $27 price target. Market leader in significantly underpenetrated market.
rated new Neutral at Lazard. Company is hurt by limited macro visibility.
upgraded ISI to Buy. $14.50 price target. Company is a potential takeover target.
downgraded at UBS to Sell from Neutral, UBS said. $28 price target. Valuation call.
downgraded at DA Davidson to Neutral, DA Davidson said. Valuation call, as the stock is up 22% year-to-date. $45 price target.
downgraded at BofA/Merrill from Neutral to Underperform, Bank of America/Merrill Lynch said. Valuation call, as the stock is up 18% year-to-date. $56 price target.
downgraded at UBS to Sell from Neutral, UBS said. $96 price target. New product distribution stalls, downside risk to estimates.
downgraded at Morgan Stanley from Equal-weight to Underweight, Morgan Stanley said. $45 price target. Stock is up 18% year-to-date, but the company is growing slower than its peers.
rated new Neutral at Nomura. Valuation call, based on a $33 price target.
STOCK COMMENTS / EPS CHANGES
target raised at Oppenheimer. Shares of AYI now seen reaching $66, Oppenheimer said. Improving order rates. Perform rating.
numbers increased at Keybanc. BGC estimates were raised through 2013, Keybanc said. Alcan purchase should add to earnings. Buy rating and new $37 price target.
numbers lowered at Jefferies. Shares of CBT now seen reaching $47, Jefferies said. Estimates also lowered on likely soft note in Q4. Buy rating.
estimates, target upped at Cantor. EMC estimates were boosted through 2013, Cantor Fitzgerald said. Company is seeing better high-end performance lower input costs. Buy rating and new $31 price target.
numbers lowered at Oppenheimer. Shares of FB now seen reaching $27, Oppenheimer said. Estimates also lowered on dramatic impact of mobile. Outperform rating.
numbers raised at Credit Suisse. Shares of FINL now seen reaching $23, according to Credit Suisse. Estimates also increased, as higher sales are driving margin expansion. Neutral rating.
estimates, target raised at Deutsche. Shares of IBM now seen reaching $240, according to Deutsche Bank. Estimates also increased, as hardware growth should re-accelerate in the near term. Buy rating.
numbers raised at Credit Suisse. Shares of LLY now seen reaching $54, according to Credit Suisse. Estimates also increased, given higher expected Ramucirumab sales. Outperform rating.
estimates, target boosted at Morgan Stanley. Shares of LOW now seen reaching $33, according to Morgan Stanley. Estimates also upped, given higher expected home prices. Overweight rating.
numbers cut at Credit Suisse. LRCX estimates were reduced through 2013, Credit Suisse said. Company is exposed to lower memory demand. Outperform rating and new $38 price target.
estimates, target boosted at Credit Suisse. Shares of MKC now seen reaching $61, according to Credit Suisse. Estimates also upped, given the company's new guidance. Neutral rating.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on